Primary study · included by 1 review

Pain Levels Did Not Differ Following Uncomplicated Third Molar Extractions Utilizing Liposomal Bupivacaine Versus Standard Bupivacaine.

James 2022 · James Jeffrey, Benton Bryan, Faigen Alexander, et al. · Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2023

Included by

Efficacy of Liposomal Bupivacaine in Third Molar Extraction: A Systematic Review and Meta-Analysis.

Non-Cochrane · intervention · 2026 · cited as James 2022 · Table 2; Figures 3-4; reference list

Outcome this study informs	Pooled effect	Evidence	Certainty
Postoperative pain intensity (VAS/NRS) Liposomal bupivacaine infiltration vs Standard bupivacaine or placebo · 0-48 hours	SMD -0.21 [-0.51, 0.10]	2 studies · 168 participants	GRADE not reported
Total opioid consumption (morphine milligram equivalents) Liposomal bupivacaine infiltration vs Standard bupivacaine or placebo · 48 hours	MD -1.20 [-1.79, -0.61]	2 studies · 174 participants	GRADE not reported
Total opioid prescription at 48 hours (MME) Liposomal bupivacaine infiltration vs Standard bupivacaine or placebo (non-LB control) · 48 hours	MD -66.70 [-72.96, -60.44]	1 study · 600 participants	GRADE not reported
Cumulative postoperative pain score (NRS) Liposomal bupivacaine infiltration vs Standard bupivacaine or placebo · 0-48 hours	SMD -1.06 [-2.52, 0.39]	2 studies · 294 participants	GRADE not reported

1 including review in total.